Literature DB >> 29492383

Current indications for transplantation: stratification of severe heart failure and shared decision-making.

Darko Vucicevic1, Lily Honoris1, Federica Raia1,2, Mario Deng1.   

Abstract

Heart failure (HF) is a complex clinical syndrome that results from structural or functional cardiovascular disorders causing a mismatch between demand and supply of oxygenated blood and consecutive failure of the body's organs. For those patients with stage D HF, advanced therapies, such as mechanical circulatory support (MCS) or heart transplantation (HTx), are potentially life-saving options. The role of risk stratification of patients with stage D HF in a value-based healthcare framework is to predict which subset might benefit from advanced HF (AdHF) therapies, to improve outcomes related to the individual patient including mortality, morbidity and patient experience as well as to optimize health care delivery system outcomes such as cost-effectiveness. Risk stratification and subsequent outcome prediction as well as therapeutic recommendation-making need to be based on the comparative survival benefit rationale. A robust model needs to (I) have the power to discriminate (i.e., to correctly risk stratify patients); (II) calibrate (i.e., to show agreement between the predicted and observed risk); (III) to be applicable to the general population; and (IV) provide good external validation. The Seattle Heart Failure Model (SHFM) and the Heart Failure Survival Score (HFSS) are two of the most widely utilized scores. However, outcomes for patients with HF are highly variable which make clinical predictions challenging. Despite our clinical expertise and current prediction tools, the best short- and long-term survival for the individual patient, particularly the sickest patient, is not easy to identify because among the most severely ill, elderly and frail patients, most preoperative prediction tools have the tendency to be imprecise in estimating risk. They should be used as a guide in a clinical encounter grounded in a culture of shared decision-making, with the expert healthcare professional team as consultants and the patient as an empowered decision-maker in a trustful safe therapeutic relationship.

Entities:  

Keywords:  Heart failure (HF); heart transplantation (HTx); mechanical circulatory support (MCS); palliation therapy; risk stratification; shared decision making; stage D

Year:  2018        PMID: 29492383      PMCID: PMC5827132          DOI: 10.21037/acs.2017.12.01

Source DB:  PubMed          Journal:  Ann Cardiothorac Surg        ISSN: 2225-319X


  65 in total

1.  Peripheral blood mononuclear cell transcriptome profiles suggest T-cell immunosuppression after uncomplicated mechanical circulatory support device surgery.

Authors:  Anshu Sinha; Khurram Shahzad; Farhana Latif; Martin Cadeiras; Manuel Prinz Von Bayern; Simin Oz; Yoshifumi Naka; Mario C Deng
Journal:  Hum Immunol       Date:  2009-10-30       Impact factor: 2.850

Review 2.  Cellular senescence: from growth arrest to immunogenic conversion.

Authors:  D G A Burton; R G A Faragher
Journal:  Age (Dordr)       Date:  2015-03-20

3.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake
Journal:  J Am Coll Cardiol       Date:  2017-04-28       Impact factor: 24.094

4.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.

Authors:  B Levine; J Kalman; L Mayer; H M Fillit; M Packer
Journal:  N Engl J Med       Date:  1990-07-26       Impact factor: 91.245

5.  Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation.

Authors:  K D Aaronson; J S Schwartz; T M Chen; K L Wong; J E Goin; D M Mancini
Journal:  Circulation       Date:  1997-06-17       Impact factor: 29.690

Review 6.  Frailty and the selection of patients for destination therapy left ventricular assist device.

Authors:  Kelsey M Flint; Daniel D Matlock; Joann Lindenfeld; Larry A Allen
Journal:  Circ Heart Fail       Date:  2012-03-01       Impact factor: 8.790

7.  Frailty and outcomes after implantation of left ventricular assist device as destination therapy.

Authors:  Shannon M Dunlay; Soon J Park; Lyle D Joyce; Richard C Daly; John M Stulak; Sheila M McNallan; Véronique L Roger; Sudhir S Kushwaha
Journal:  J Heart Lung Transplant       Date:  2013-12-27       Impact factor: 10.247

Review 8.  Advanced heart failure: a call to action.

Authors:  Stuart D Russell; Leslie W Miller; Francis D Pagani
Journal:  Congest Heart Fail       Date:  2008 Nov-Dec

9.  Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project.

Authors:  Mark D Huffman; Jarett D Berry; Hongyan Ning; Alan R Dyer; Daniel B Garside; Xuan Cai; Martha L Daviglus; Donald M Lloyd-Jones
Journal:  J Am Coll Cardiol       Date:  2013-04-09       Impact factor: 24.094

10.  Comparison of whole blood and peripheral blood mononuclear cell gene expression for evaluation of the perioperative inflammatory response in patients with advanced heart failure.

Authors:  Galyna Bondar; Martin Cadeiras; Nicholas Wisniewski; Jetrina Maque; Jay Chittoor; Eleanor Chang; Maral Bakir; Charlotte Starling; Khurram Shahzad; Peipei Ping; Elaine Reed; Mario Deng
Journal:  PLoS One       Date:  2014-12-17       Impact factor: 3.240

View more
  1 in total

1.  Development of 3D PVA scaffolds for cardiac tissue engineering and cell screening applications.

Authors:  Elisabetta Dattola; Elvira Immacolata Parrotta; Stefania Scalise; Gerardo Perozziello; Tania Limongi; Patrizio Candeloro; Maria Laura Coluccio; Carmine Maletta; Luigi Bruno; Maria Teresa De Angelis; Gianluca Santamaria; Vincenzo Mollace; Ernesto Lamanna; Enzo Di Fabrizio; Giovanni Cuda
Journal:  RSC Adv       Date:  2019-02-14       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.